Authors
Latest:
ASCO GU 2022: Piecing Together Prostate Cancer Data With Drs. Tanya Dorff and Jathin BandariOncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.
Latest:
Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some PatientsMount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.
Latest:
Dr Singer on the Safety of Perioperative Nivolumab and Cabozantinib in RCCEric A. Singer, MD, discusses the safety of perioperative nivolumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma.
Latest:
Advances in Targeted Therapy, Treatment Disparities Among Cancer Conference TalksTargeted therapy, genomics, and treatment disparities were among the topics that were presented by researchers from UCSF at the 2024 AACR conference.
Latest:
Dr. Mai on Barriers of Genetic Testing in CRCPhuong L. Mai, MD, discusses barriers of genetic testing in colorectal cancer.
Latest:
Creating the In-Person Experience on a Virtual PlatformThe coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.
Latest:
Dr. Crown on the Investigation of Lapatinib Plus Chemotherapy in HER2+ Breast CancerJohn Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.
Latest:
Women in Oncology: Self-Advocacy in a Busy FieldMelinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.
Latest:
Dr O'Cearbhaill on Results With Ubamatamab Plus Cemiplimab in Recurrent Ovarian CancerRoisin E. O'Cearbhaill, MD, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer.
Latest:
Charting the Course for Patients With High-Risk Colon Cancer: 3 Months Versus 6 MonthsIn 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.
Latest:
Considering Novel Therapy for HER2+ Metastatic Breast CancerA summary of sequencing therapy in the HER2+ metastatic breast cancer treatment paradigm followed by excitement for novel therapies under investigation.
Latest:
Dr. D’Souza on the Utilization of Monoclonal Antibodies and Immunomodulating Agents in AL AmyloidosisAnita D’Souza, MD, discusses the utilization of monoclonal antibodies and immunomodulating agents in patients with light chain amyloidosis.
Latest:
Dr Krause on GLP-1 Receptor Agonist Therapy in Endometrial CancerDanielle Krause, MD, discusses the effects of GLP-1 receptor agonist therapy in endometrial cancer.
Latest:
Important Considerations for Biomarker Testing in NSCLC at Key Points in Treatment JourneyThe biomarker testing landscape has evolved over the years, affecting how oncologists approach lung cancer.
Latest:
Primary Overall Survival Analysis of the Phase 3 Randomized ZUMA‑7 Study of Axicabtagene Ciloleucel Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell LymphomaJason R. Westin, MD, MS, FACP, presents the overall survival analysis from ZUMA-7, a phase 3 study investigating axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Latest:
Dr. Piliè on the Benefit of Second-Generation AR Inhibitors in Nonmetastatic CRPCPatrick Piliè, MD, discusses the benefit of second-generation androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Latest:
Dr. Naqash and Dr. Chen on the Efficacy of Atezolizumab in Advanced Alveolar Soft Part SarcomaAbdul Rafeh Naqash, MD, and Alice Chen, MD, discuss their phase 2 trial evaluating the efficacy of atezolizumab in patients with advanced alveolar soft part sarcoma.
Latest:
CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through AccountabilityAlthough the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.
Latest:
Dr Sinno on Molecular Characterization in Endometrial CancerAbdulrahman Sinno, MD, discusses the shift in focus to molecular characteristics of endometrial cancer.
Latest:
Dr. Zauderer on the Importance of Optimizing Care in MesotheliomaMarjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.
Latest:
JAK Inhibitors Continue to Shape the Treatment Landscape of MyelofibrosisFollowing the FDA approvals of the JAK inhibitors ruxolitinib, fedratinib, and pacritinib, the treatment landscape of myelofibrosis continues to grow with the use of these agents with an additional FDA review planned for momelotinib in September 2023.
Latest:
Dr Stintzing on the Safety Profile of Fruquintinib in mCRCSebastian Stintzing, MD, discusses the Q-TWiST analysis of fruquintinib plus best supportive care in metastatic colorectal cancer.
Latest:
Dr Katims on the Feasibility of scRNA-seq in FGFR3+ Upper Tract Urothelial CarcinomaAndrew Katims, MD, MPH, discusses the feasibility of using single-cell RNA-sequencing in FGFR3-mutated upper tract urothelial carcinoma
Latest:
Dr Hoppe on Outcomes of the CheckMate 744 Trial in Hodgkin LymphomaBradford (Brad) S. Hoppe, MD, MPH, discusses the rationale for investigating consolidative radiotherapy in place of autologous stem cell transplant in patients with low-risk, relapsed/refractory classic Hodgkin lymphoma who have been previously treated with nivolumab plus brentuximab vedotin, as investigated in the phase 2 CheckMate 744 study, as well as key findings from this trial.
Latest:
Dr Ryan on the Role of Adjuvant Therapy in RCCChristopher W. Ryan, MD, discusses the role of adjuvant therapy for patients with renal cell carcinoma.
Latest:
Dr. Winter on Emerging Agents in CLLAllison Winter, MD, discusses emerging agents in chronic lymphocytic leukemia.
Latest:
Operational Processes and ChallengesMark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.
Latest:
Dr Blanco on Unmet Needs for Pediatric Patients With Relapsed Brain TumorsJezabel Rodriguez-Blanco, PhD, discusses unmet needs for pediatric patients with relapsed brain tumors, including the need for additional treatment approaches for these patients.
Latest:
Dr. Simons on Racial Disparities Reported in Luminal Breast CancerYael Simons, MD, discusses the racial disparities seen in African Americans patients with luminal breast cancer.
